All Updates

All Updates

icon
Filter
Product updates
Navigate BioPharma services launches new assay for radioligand therapies in tumors
Precision Medicine
May 31, 2024
This week:
M&A
Funding
TravelPerk raises USD 135 million in debt funding for expansion; acquires AmTrav
Travel Tech
Yesterday
Product updates
Apple announces Apple Pay Later shutdown
Buy Now, Pay Later
Jun 17, 2024
Management news
Velo3D appoints Brad Kreger as permanent CEO
Additive Manufacturing
Jun 17, 2024
Partnerships
Perplexity partners with SoftBank for AI search engine promotion in Japan
Generative AI Applications
Jun 17, 2024
Product updates
Runway launches Gen-3 Alpha for generating video clips
Generative AI Applications
Jun 17, 2024
Product updates
Adobe integrates Firefly into Acrobat with chat support across multiple documents in Acrobat AI Assistant
Generative AI Applications
Jun 17, 2024
Funding
Amplify Life raises USD 20 million in Series B to expand product suite
InsurTech: Personal Lines
Jun 17, 2024
Funding
Tinybird raises USD 30 million in Series B funding to improve real-time data analytics platform
Data Infrastructure & Analytics
Jun 17, 2024
Partnerships
The EVERY Company collaborates with Grupo Palacios to develop hen-less omelets
Plant-based Dairy & Egg
Jun 17, 2024
Partnerships
Believer Meats partners with AGWA to propel cultivated meat industry in MENA region
Cell-cultured Meat
Jun 17, 2024
Precision Medicine

Precision Medicine

May 31, 2024

Navigate BioPharma services launches new assay for radioligand therapies in tumors

Product updates

  • Navigate BioPharma Services has launched a new assay to measure and quantify the impact of radioligand therapies on tumor markers. The development of the assay was presented at the American Association for Cancer Research (AACR) 2024 Annual Meeting in California.

  • The assay is designed to measure changes in cancerous cells and tissue post-radioligand therapy using multiplex immunofluorescence (mIF) and automated quantitative analysis (AQUA) algorithms to precisely calculate variations in key protein markers within tumor tissues. The key features of the product include multiplex analysis, AQUA algorithms, and high sensitivity to subtle changes in protein levels. 

  • Navigate BioPharma Services, a subsidiary of Novartis, offers specialty laboratory services, including biomarker, bioanalytical, and diagnostic support services and clinical trial services. The company’s services span multiple therapeutic areas, including oncology, hematology, neurology, and rare diseases. Navigate BioPharma focuses on developing new biomarker solutions and custom validations to support drug development from discovery phases to clinical trials.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.